{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"22"}]}],"title":"CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Complete response (CR) (all of the following):\n\n1. Negative immunofixation in serum and urine.\n2. \\< 5% plasma cells in the bone marrow.\n3. Disappearance of any soft tissue plasmacytomas.\n\nVery good partial response (VGPR) (one of the following):\n\n1. Serum and urine M protein detectable by immunofixation but not by electrophoresis.\n2. 90% or greater reduction in serum M protein plus urine M protein level \\<100 mg per 4h.","groups":[{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG000","title":"P1_C1_5x10^6"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG001","title":"P1_C2_1x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG002","title":"P1_C3_5x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG003","title":"P1_C4_1X10^8"},{"description":"Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"OG004","title":"P2_1x10^8+Elotuzumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 3 months post-transplant","title":"Number of Participants That Achieved Very Good Response (VGPR) + Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"Participants"}